Brief: IX Biopharma Says Received Positive Feedback From European Medicines Agency Regarding Wafermine
10/11/2020 07:34
Nov 10 (Reuters) - IX Biopharma Ltd IXBI.SI :
* RECEIVED POSITIVE FEEDBACK FROM EUROPEAN MEDICINES AGENCY
REGARDING ITS PHASE 3 CLINICAL DEVELOPMENT PROGRAMME FOR
WAFERMINE
Source text for Eikon: ID:nSNqYzvt
Further company coverage: IXBI.SI
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IX Biopharma
See all newsBrief: IX Biopharma Says Co Will Undertake An Internal Restructuring Of Its Consumer Business
Brief: IX Biopharma To Issue 1 MLN New Shares To Anson Properties At S$0.4215 Per Share
Brief: IX Biopharma Says US Government Awards US$41 MLN Contract To Fund Development Of Wafermine
Brief: IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per Share
Brief: IX Biopharma Enters Term Sheet For Proposed Joint Venture